One of the less-discussed questions in nicotine research is what happens to former smokers who use e-cigarettes or other alternative nicotine products after quitting. The cessation literature has focused primarily on whether these products help smokers quit, but the relapse prevention question is arguably more policy-relevant given how common post-cessation relapse is and how significant the long-term health consequences of returning to combustible tobacco are.
A new body of research is beginning to examine this question more systematically. Preliminary findings suggest that continued use of electronic cigarettes after smoking cessation is associated with lower relapse rates over 12-month follow-up periods compared to cessation without any nicotine replacement. This would be consistent with what is known about nicotine dependence — that the craving dimensions of dependence can persist long after acute withdrawal symptoms resolve — and suggests that maintaining nicotine delivery through a lower-risk product may provide a protective buffer during high-risk relapse periods.
The implication for nicotine pouches is direct. If the relapse prevention benefit is real and attributable to nicotine delivery rather than the specific product format, pouches might serve a similar function. They are more discreet than e-cigarettes, have no aerosol exposure concerns, and may be more acceptable to former smokers in settings where vaping is restricted. Whether this translates to equivalent or superior relapse prevention outcomes is not yet known, but the mechanistic rationale is plausible.
The research also has implications for how treatment guidelines handle alternative nicotine products post-cessation. Current guidelines in many countries counsel against indefinite use of nicotine replacement therapies, including e-cigarettes, after smoking cessation. If continued use reduces relapse risk, the trade-off calculation changes significantly — particularly given that the health risk of continued pouch or e-cigarette use is substantially lower than the risk of returning to cigarettes.
This is an area where the research agenda needs to develop quickly. The population of former smokers who have switched to alternative products is large and growing, and the evidence base for guiding their ongoing use decisions remains thin relative to what would be needed for confident clinical recommendations.
